D3-002A Phase 1A/B study to evaluate the safety and tolerability of ET-1922159 in advanced solid tumours
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting
Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Atezolizumab in Combination with Chemotherapy for Patients with Early Relapsing Recurrent (Inoperable Locally Advanced or Metastatic) Triple-Negative Breast Cancer
A phase II study to compare the safety and efficacy of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-expressing recurrent advanced or metastatic endometrial carcinoma who previously progressed on or after first line platinum-based chemotherapy
NCCS-OTSP-HCC1 / MK-3475-750
Longitudinal Immune-phenotyping of Surgically Resected HCC following Neoadjuvant and Adjuvant Treatment with MK – 3475
Metastatic or recurrent nasopharyngeal carcinoma
No more than 1 line
ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Advanced curatively unresectable solid tumors failing standard therapy.
HCC: must have failed at least 1 line of standard therapy
Gastric cancer: must have failed at least 2 line of standard therapy (inclusive of adjuvant treatment)
Other solid tumours: must have failed at least 1 line of standard therapy
Subscribe to our mailing list to get the updates to your email inbox...
11 Hospital Crescent, Singapore 169610 +65 6436 8000